Chemoinformaics analysis of 3,4-Dihydro-1H-2-benzopyran-1-one
| Molecular Weight | 148.161 | nRot | 0 |
| Heavy Atom Molecular Weight | 140.097 | nRig | 12 |
| Exact Molecular Weight | 148.052 | nRing | 2 |
| Solubility: LogS | -2.568 | nHRing | 1 |
| Solubility: LogP | 2.286 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 19 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 1 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 8 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 6 |
| nHA | 2 | APOL | 21.9683 |
| nHD | 0 | BPOL | 10.6297 |
| QED | 0.52 |
| Synth | 1.871 |
| Natural Product Likeliness | 0.142 |
| NR-PPAR-gamma | 0.01 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.002 |
| Pgp-sub | 0 |
| HIA | 0.004 |
| CACO-2 | -4.415 |
| MDCK | 0.0000306 |
| BBB | 0.331 |
| PPB | 0.870678 |
| VDSS | 2.437 |
| FU | 0.101332 |
| CYP1A2-inh | 0.976 |
| CYP1A2-sub | 0.434 |
| CYP2c19-inh | 0.895 |
| CYP2c19-sub | 0.1 |
| CYP2c9-inh | 0.237 |
| CYP2c9-sub | 0.621 |
| CYP2d6-inh | 0.125 |
| CYP2d6-sub | 0.701 |
| CYP3a4-inh | 0.047 |
| CYP3a4-sub | 0.189 |
| CL | 12.056 |
| T12 | 0.723 |
| hERG | 0.049 |
| Ames | 0.046 |
| ROA | 0.023 |
| SkinSen | 0.641 |
| Carcinogencity | 0.492 |
| EI | 0.991 |
| Respiratory | 0.043 |
| NR-Aromatase | 0.026 |
| Antiviral | No |
| Prediction | 0.844412 |